Mitoxantrone is a synthetic antineoplastic anthracenedione for intravenous use. It indicated for reducing neurologic disability and/or the frequency of clinical relapses in patients with secondary (chronic) progressive, progressive relapsing, or worsening relapsing-remitting multiple sclerosis (i.e., patients whose neurologic status is significantly abnormal between relapses). It is also used to treat certain cancers. Mitoxantrone is not indicated in the treatment of patients with primary progressive multiple sclerosis. The brand name Novantrone is no longer manufactured and the drug is only available as generic. Mitoxantrone has a black box warning for cardiotoxicity. It is seldom prescribed due to its high risk profile and frequency of severe adverse events. It should only be prescribed if the potential benefits greatly outweigh the risks.

Mitoxantrone will be considered for coverage when the following criteria are met:

**Multiple Sclerosis (MS)**

For initial authorization:
1. Member must be 18 years of age or older; AND
2. Medication must be prescribed by, or in consultation with, a neurologist; AND
3. Chart notes have been provided confirming diagnosis of one of the following types of MS:
   a) Secondary (chronic) progressive
   b) Progressive relapsing
   c) Worsening relapsing-remitting (i.e., member’s neurologic status is significantly abnormal between relapses); AND
4. Member has had all of the baseline assessments below and does NOT have any of the following:
   a) Abnormal liver function tests
   b) LVEF less than 50%
   c) Neutrophil count less than 1500 cells/mm³
   d) Exceeded maximum cumulative lifetime dose for mitoxantrone of 140 mg/m²; AND
5. Member’s condition continues to decline despite compliant trial and failure of at least 3 prior disease-modifying drugs indicated for MS at the max tolerated doses; AND
6. Member does NOT have primary progressive MS.
7. Dosage allowed/Quantity limit: 12 mg/m² infusion every 3 months (Maximum cumulative lifetime dose is 140 mg/m²)
   QL: 5 units per 84 days

*If all the above requirements are met, the medication will be approved for 12 months.*
For **reauthorization**:  
1. Chart notes must document reduced neurologic disability or reduced frequency of relapses; AND  
2. Member's LVEF is being monitored prior to each dose; AND  
3. Member has not exceeded the maximum cumulative lifetime dose of 140 mg/m².  

*If all the above requirements are met, the medication will be approved for an additional 12 months.*

### Cancer diagnosis

Any request for oncology use must be submitted through [NantHealth/Eviti](https://nanthealth.com) portal.

**CareSource considers mitoxantrone not medically necessary for the treatment of conditions that are not listed in this document. For any other indication, please refer to the Off-Label policy.**

<table>
<thead>
<tr>
<th>DATE</th>
<th>ACTION/DESCRIPTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>06/12/2017</td>
<td>New policy for Novantrone created. Not covered diagnosis added.</td>
</tr>
<tr>
<td>12/06/2017</td>
<td>Confirmation of diagnosis based on McDonald criteria is no longer required.</td>
</tr>
<tr>
<td>07/06/2022</td>
<td>Transferred to new template. Updated all references. Specified and defined “worsening” relapsing-remitting disease. Added PRMS as a use and PPMS as an exclusion. Added baseline monitoring assessments. Changed step drugs from 2 to at least 3. Changed QL from per infusion to per 3 months (per label). Added reduced neurologic disability or reduced frequency of relapses to renewal criteria, split off the max cumulative dose as an additional criterion.</td>
</tr>
</tbody>
</table>

References:


Effective date: 01/01/2023
Revised date: 07/06/2022